Home > News > Headline News > Archive

Click on title to read the full article.

Author Insights: Incidence of Advanced Breast Cancer May Be Increasing in Young US Women

February 27, 2013

By news@JAMA

Lead author Rebecca H. Johnson, MD, of Seattle Children’s Hospital and the University of Washington, discusses her team’s findings on the JAMA study published today about an increase in metastatic breast cancer incidence in young women.

Deadly breast cancers rising in young women

February 27, 2013

By Liz Szabl, USA Today

At a time when the USA is making progress overall against cancer, a new study suggests a worrisome rise in the number of young women diagnosed with advanced, incurable breast cancer.

Notion of Using Herceptin Only for HER2-Positive Breast Cancer Challenged

February 27, 2013

By Science Daily

New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative -- and that the drug Herceptin, which targets HER2, may have an even greater role for treating breast cancer and preventing its spread. A recent study based on new analyses of old data found some tumors were incorrectly categorized as HER2-positive and as a result those women received adjuvant Herceptin. It turns out, they benefited as much from the treatment as woman with actual HER2-positive cancer.

Researchers discover link between inflammation and spread of breast cancer

February 24, 2013

By Anne Ju, Cornell Chronicle

Cancer is lethal because it spreads, or metastasizes, and curing cancer depends on knowing just how this process works. Cornell biomedical engineers have uncovered a groundbreaking link between the body's natural inflammatory response, and how malignant breast cancer cells use the bloodstream to metastasize

FDA Approves Genentech’s Kadcyla (TDM1)

February 23, 2013

By FDA Press Release

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved KadcylaTM (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin® (trastuzumab) and a taxane chemotherapy.

An antibody-drug conjugate (ADC) is a new kind of targeted cancer medicine that can attach to certain types of cancer cells and deliver chemotherapy directly to them. Kadcyla is the first FDA-approved ADC for treating HER2-positive mBC, an aggressive form of the disease.


Five year survival rates can mislead – message to medical educators, medical journals, journalists and the public

February 7, 2013

By Gary Schwitzer, Health News Review.org

Professor Gerd Gigerenzer of the Max Planck Institute in Berlin published an article in the BMJ last week, “Five year survival rates can mislead.”

FDA approval of generic version of cancer drug Doxil is expected to help resolve shortage

February 5, 2013

By FDA Press Release

The U.S. Food and Drug Administration today approved the first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection).

Doxorubicin hydrochloride liposome injection is currently on the FDA’s drug shortage list. For products on the shortage list, the FDA’s Office of Generic Drugs is using a priority review system to expedite the review of generic applications to help alleviate shortages.